Evidence map›Paper›PMID 39204223›Full record

Observational studyPathogens (Basel, Switzerland)2024

Deciphering the Longevity and Levels of SARS-CoV-2 Antibodies in Children: A Year-Long Study Highlighting Clinical Phenotypes and Age-Related Variations.

Gemma Pons-Tomàs, Rosa Pino, Aleix Soler-García, Cristian Launes, Irene Martínez-de-Albeniz, María Ríos-Barnés, Maria Melé-Casas, María Hernández-García, Manuel Monsonís, Amadeu Gené and 4 more

Abstract readObservational Study
In one paragraph

Observational study in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gemma Pons-TomàsPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.ORCID 0000-0001-6035-7106
Rosa PinoPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.
Aleix Soler-GarcíaPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.
Cristian LaunesPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.ORCID 0000-0002-0913-9303
Irene Martínez-de-AlbenizInfectious and Imported Diseases Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain.
María Ríos-BarnésInfectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu (IRSJD), 08950 Barcelona, Spain.
Maria Melé-CasasPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.
María Hernández-GarcíaPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.
Manuel MonsonísDepartment of Microbiology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain.
Amadeu GenéDepartment of Microbiology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain.ORCID 0000-0003-0059-8607
Mariona-F de-SevillaPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.
Juan-José García-GarcíaPaediatric Department, Hospital Sant Joan de Déu, University of Barcelona, 08950 Barcelona, Spain.ORCID 0000-0002-3483-528X
Claudia FortunyInfectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu (IRSJD), 08950 Barcelona, Spain.
Victoria FumadóInfectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu (IRSJD), 08950 Barcelona, Spain.

Funding

Banco SantanderKids Corona platformStavros Niarkos Foundation
6 · The paper itself

Abstract

backgroundIdentifying potential factors correlated with the sustained presence of antibodies in plasma may facilitate improved retrospective diagnoses and aid in the appraisal of pertinent vaccination strategies for various demographic groups. The main objective was to describe the persistence of anti-spike IgG one year after diagnosis in children and analyse its levels in relation to epidemiological and clinical variables.

methodsA prospective, longitudinal, observational study was conducted in a university reference hospital in the Metropolitan Region of Barcelona (Spain) (March 2020-May 2021). This study included patients under 18 years of age with SARS-CoV-2 infection (positive PCR or antigen tests for SARS-CoV-2). Clinical and serological follow-up one year after infection was performed.

resultsWe included 102 patients with a median age of 8.8 years. Anti-spike IgG was positive in 98/102 (96%) 12 months after the infection. There were higher anti-spike IgG levels were noted in patients younger than 2 years (

conclusionAnti-SARS-CoV-2 IgG antibodies were detected in almost all paediatric patients one year after infection. We also observed a positive correlation between virus-specific IgG antibody titres with SARS-CoV-2 clinical phenotype (pneumonia) and age (under 2 years old).

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin GSARS-CoV-2AdolescentAge FactorsChildChild, PreschoolFemaleHumansInfantLongitudinal StudiesMalePhenotypeProspective StudiesSpainAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodieshospitalisationpaediatricsSARS-CoV-2serology

Identifiers

PMID39204223
PMCPMC11357146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.